Clinical trials: Alzheimer Disease 5
Colorectal Cancer, Lung Cancer
QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA
The purpose of this study is to find out what effects (good and bad) that a cancer vaccine has on you and your cancer. The cancer vaccine is called Ad5 [E1-, E2b-]-CEA(6D)or ETBX-011 and is made by Etubics.
- Conditions
- Colorectal Cancer, Lung Cancer, Breast Cancer, Prostate Cancer
- Trial name
- NCT01147965
- Testing
- Ad5 CEA Vaccine
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- NantCell, Inc.
Pancreas Cancer
An Exploratory Trial to Evaluate Efficacy and Safety for Combination Treatment of Adenovirus Double Suicide Gene Therapy
Replication-competent Adenovirus-mediated Double Suicide Gene Therapy (Theragene®,Ad5-yCD/mutTKSR39rep-ADP) showed safety and anti-cancer effect in patients with pancreatic cancer in phase I study.
- Trial name
- NCT04739046
- Testing
- Theragene arm
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Seoul National University Bundang Hospital
Alzheimer Type Dementia
An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia
The purpose of this study is to evaluate the efficacy and safety of two fixed dose (1200mg/day, 1600mg/day) of INM-176 (a drug of treating dementia) comparing with donepezil for treatment for patients with Alzheimer type dementia.
- Trial name
- NCT01245530
- Testing
- Aricept, INM-176
- Where
- South Korea
- Volunteers
- 280 people
- Sponsor
- Whanin Pharmaceutical Company
COVID-19
Heterologous Prime-boost Immunization with an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Priming with an Inactivated SARS-CoV-2 Vaccine
This is a randomized, open-label, parallel-controlled study to evaluate the safety and immunogenicity of heterologous prime-boost immunization with an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) after…
- Trial name
- NCT05043259
- Testing
- inactive SARS-CoV-2 vaccine (Vero cell), Low dose aerosolized Ad5-nCoV, High dose aerosolized Ad5-nCoV
- Where
- China
- Volunteers
- 423 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Patients Aged 65-85 (Both Included), Diagnosed of Mild Cognitive Impairment
Diabetes as an Accelerator of Cognitive Impairment and Alzheimer's Disease
This randomized controlled trial is aimed at studying the effects of an eHealth intervention on improving metabolic control and other cardiovascular risk factors (obesity, lipidic profile and hypertension) as the approach to…
- Conditions
- Patients Aged 65-85 (Both Included), Diagnosed of Mild Cognitive Impairment, Diagnosed of Type 2 Diabetes in Active Treatment (Hypoglycemic Agents) for a Period ≥5 Years
- Trial name
- DIALCAT (NCT03578991)
- Testing
- Smart pillbox, Interactive digital platform
- Where
- 8 sites in Spain
- Volunteers
- 54 people
- Sponsor
- Parc Sanitari Pere Virgili
Dementia Alzheimer's Type
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
Primary Objective: To demonstrate the efficacy of at least one dose of SAR110894 (H3 receptor antagonist) in comparison to placebo on cognitive performance in patients with mild to moderate Alzheimer's disease (AD) while on…
- Trial name
- NCT01266525
- Testing
- SAR110894, Donepezil
- Where
- 82 sites in United States, Australia and 7 more
- Volunteers
- 291 people
- Sponsor
- Sanofi
Cystic Fibrosis
Phase I Pilot Study of Ad5-CB-CFTR, an Adenovirus Vector Containing the Cystic Fibrosis Transmembrane Conductance Regulator Gene, in Patients With Cystic Fibrosis
OBJECTIVES: I. Assess the safety and efficacy of gene transfer into the nasal epithelium using Ad5-CB-CFTR, an E1-deleted adenovirus vector containing the cystic fibrosis transmembrane conductance regulator gene, in patients with…
- Trial name
- NCT00004779
- Testing
- Ad5-CB-CFTR
- Volunteers
- 12 people
- Sponsor
- National Center for Research Resources (NCRR)
COVID-19
Heterologous Boost Immunization with an Aerosolised Ad5-nCoV After Two-dose Priming with an Inactivated SARS-CoV-2 Vaccine
This is a multicenter, open-label, partially radomized, parallel-controlled clinical trial to evaluate the safety and immunogenicity of heterologous prime-boost immunization with an aerosolised adenovirus type-5 vector-based…
- Trial name
- NCT05204589
- Testing
- Aerosolized Ad5-nCoV, Inactivated SARS-CoV-2 vaccine
- Where
- China
- Volunteers
- 10,285 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Neoplasms, Prostate Cancer
Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer
Background: ETBX-011, ETBX-061, and ETBX-051 are cancer vaccines. Their goal is to teach the immune system to target and kill cancer cells. The vaccines target 3 proteins found in many types of cancer.
- Conditions
- Neoplasms, Prostate Cancer, Lung Cancer, Breast Cancer
- Trial name
- NCT03384316
- Testing
- ETBX-051; adenoviral brachyury vaccine, ETBX-061; adenoviral Mucin-1 (MUC1) vaccine, ETBX-011; adenoviral Carcinoembryonic antigen (CEA) vaccine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Alzheimer Disease, Dementia
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
The reason for this study is to assess the safety and efficacy of donanemab in participants with early Alzheimer's disease. The study duration including screening and follow-up is up to 93 weeks.
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- NCT05508789
- Testing
- Donanemab
- Where
- 141 sites in Argentina, Australia and 6 more
- Volunteers
- 1,500 people
- Sponsor
- Eli Lilly and Company
COVID-19, SARS-CoV2 Infection
Phase 1 Trial of ChAd68 and Ad5 Adenovirus COVID-19 Vaccines Delivered by Aerosol
This is a phase 1 study in healthy volunteers who have received at least three doses of an mRNA COVID-19 vaccine, to evaluate the safety and immune responses that develop in the blood and lungs following the administration by…
- Trial name
- NCT05094609
- Testing
- Ad5-triCoV/Mac, ChAd-triCoV/Mac
- Where
- Canada
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- McMaster University
COVID-19
Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above
This study is a global multicenter, randomized, double-blind, placebo -controlled, adaptive designed phase Ⅲ clinical trial, in order to evaluate the efficacy, safety and immunogenicity of Recombinant Novel Coronavirus Vaccine…
- Trial name
- NCT04526990
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Where
- 74 sites in Argentina, Chile and 3 more
- Volunteers
- 44,247 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Covid19
Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19
This study is a phase III clinical trial to evaluate efficacy, reactogenicity and safety of the vaccine Ad5-nCoV compared with placebo in volunteers at the age from 18 to 85 years，with the randomized, double-blind design
- Trial name
- NCT04540419
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Where
- 7 sites in Russia
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- NPO Petrovax
Alzheimer Dementia (AD)
Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer
Evaluation of the safety and tolerability of a 20 mg once daily dose of memantine compared with 10 mg given twice daily in patients with dementia of Alzheimer's type and MMSE range 5-18.
- Trial name
- NCT02553928
- Testing
- Memantine (once daily), Memantine (twice daily)
- Where
- 6 sites in China
- Volunteers
- 62 people
- Sponsor
- H. Lundbeck A/S
COVID-19
A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
This study is a randomized, double-blind, placebo -controlled IIb clinical trial, in order to evaluate the safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in people 6 years old and…
- Trial name
- NCT04566770
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Colon Cancer
Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer
The purpose of this study is to determine the safety, tolerability and ability to stimulate hGCC-specific antibody and killer T cell immune responses of an Ad5-hGCC-PADRE vaccine in stage I and stage II Caucasian and African…
- Trial name
- NCT01972737
- Testing
- Ad5-hGCC-PADRE vaccine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
AIDS, HIV Infections
Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023)
This study will test the safety and efficacy of an investigational Human Immunodeficiency Virus (HIV) vaccine. Efficacy will be measured by either prevention of HIV infection or control of HIV viral load in subjects who become…
- Trial name
- NCT00095576
- Testing
- Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose)
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer's Disease
Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid
The purpose of this study was to evaluate the efficacy and safety of plasma exchange with 5% albumin in beta-amyloid peptide clearance in cerebrospinal fluid, and its effects in patients with mild-moderate Alzheimer's disease.
- Trial name
- NCT00742417
- Testing
- Albutein 5%, Control
- Where
- 4 sites in United States, Spain
- Volunteers
- 42 people
- Sponsor
- Instituto Grifols, S.A.
Thyroid Cancer, Colon Cancer
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
This is a phase 1b/2 study to evaluate the safety, tolerability, and efficacy of ETBX-011 vaccine used in combination with ALT-803 in subjects with locally advanced or metastatic CEA-expressing cancers whose tumor has recurred…
- Conditions
- Thyroid Cancer, Colon Cancer, Ovarian Cancer, Breast Cancer
- Trial name
- NCT03127098
- Testing
- ETBX-011, ALT-803
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- NantCell, Inc.
COVID-19
Heterologous Boost Immunization with Ad5-nCoV After Three-dose Priming with an Inactivated SARS-CoV-2 Vaccine
This is an open-label, randomized, parallel-controlled clinical trial to evaluate the safety and immunogenicity of heterologous prime-boost immunization with an aerosolized (Ad5-nCoV-IH) or intramuscular (Ad5-nCoV-IM) Ad5-nCoV…
- Trial name
- NCT05303584
- Testing
- Ad5-nCoV-IH, Ad5-nCoV-IM, CoronaVac
- Where
- China
- Volunteers
- 362 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention